Request Sample Inquiry
Contrast Media/Contrast Agents Market

Contrast Media/Contrast Agents Market

Contrast Media/Contrast Agents Market - Global Industry Assessment & Forecast

Number Of Pages # Pages:

146

Base Year:

2021

Date

Mar - 2022

Format:

PDF XLS PPT

Report Code:

VMR-1424

Segments Covered
  • By Type Iodinated Contrast Media, Gadolinium- Based Contrast Media, Microbubble Contrast Media, Barium- Based Contrast Media
  • By Modality X- Ray/ CT, MRI, Ultrasound
  • By Administration Intravascular Route, Oral Route, Rectal Route, Others
  • By Indication Cardiovascular Disorders, Cancer, Gastrointestinal Disorders, Musculoskeletal Disorders, Neurological Disorders, Nephrological Disorders
  • By Application Radiology, Interventional Radiology, Interventional Cardiology
  • By End User Hospital, Clinics, & Ambulatory Surgery Centers, Diagnostic Imaging Centers
  • By Regions North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Forecast YearsForecast Years: 2022 - 2028
Historical YearsHistorical Years: 2016 - 2021
Revenue 2021Revenue 2021: USD 4,729.20 Million
Revenue 2028Revenue 2028: USD 5,813.30 Million
Revenue CAGRRevenue CAGR (2022 - 2028): 3.5%
Fastest Growing Region Fastest Growing Region (2022 - 2028) Asia Pacific
Largest Region Largest Region (2021): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report
  • Go To Market Strategy
  • Region Specific Market Dynamics
  • Region Level Market Share
  • Import Export Analysis
  • Production Analysis
  • Others Request Customization Speak To Analyst
Contrast Media/Contrast Agents Market Share

Market Synopsis:

Global Contrast Media/Contrast Agents Market is valued at USD 4,729.20 Million in 2021 and is projected to reach a value of USD 5,813.30 Million by 2028 at a Compound Annual Growth Rate (CAGR) of 3.5% over the forecast period.

Contrast agents, also known as Contrast Media, are commonly used to improve the diagnostic value of imaging modalities such as ultraviolet, CT scan, and MRI by increasing the contrast of structures and fluids in the human body. These contrast agents differentiate abnormal conditions from normal healthy conditions. Iodinated, barium-based, gadolinium-based, and micro bubble are some of the commonly used contrast agents and are administered by different routes including oral, intravascular, and rectal using a contrast agent syringe.

Contrast Media/Contrast Agents Market Size, 2021 To 2028 (USD Million)

A key factor behind the upsurge in demand for contrast agents is the increased prevalence of cancer, cardiovascular disorders, and neurological diseases. Improving medical infrastructure, rise in adoption of advanced diagnostic systems in hospitals and diagnostic centers, along with the increasing number of ultrasounds, MRI, and CT examinations are expected to augment the target market growth to a significant extent. Furthermore, increasing focus on developing novel and cost-effective contrast agents, coupled with increasing initiatives and funding by various public and private organizations are expected to boost the target market growth in the next coming years.

Market Segmentation:

Below tree is interactive. You can click the nodes to get more information.

Iodinated Segment is Expected to Witness Growth at a Rapid Rate During the Forecast Period

Iodinated Contrast Media segment accounts for the largest share of the Contrast Media/Contrast Agents Market, which is attributed to the growing number of angioplasty procedures performed globally.

The X-ray/CT Segment is Expected to Dominate the Market and Account for the Largest Revenue Share

The wide acceptance and cost-effectiveness of X-ray/CT modalities has prompted the adoption of contrast agents for this modality type. X-ray/CT-based contrast agents include iodinated and barium-based contrast agents, which are used in diagnostic procedures for many diseases and are less expensive.

In MRI, contrast agent reduces the relaxation time of nuclei in the body tissues to modify the contrast in image. Gadolinium is used as a contrast agent in MRI. In the 3+ oxidation state, metals have seven unpaired electrons, which cause the water around contrast agent to relax rapidly, improving the quality of MRI scans. MRI Contrast Media is widely used to enhance and improve the contrast difference between normal and abnormal tissues. It may be administered intravenously or orally.

Cardiovascular Disorders Segment is Expected to Witness Significant Growth Rate Over the Forecast Period

Cardiovascular disease accounts for the largest market share and highest growth rate in the target market in the next coming years. Increasing geriatric population and increasing prevalence of cardiovascular disease globally are factors expected to proliferate growth of this segment in the Global Contrast Media/Contrast Agents Market.

North America Region to Continue its Domination Over the Contrast Media/Contrast Agents Market

North America market is projected to dominate the Global Contrast Media/Contrast Agents Market over the forecast period, followed by Europe. This can be attributed to growing geriatric population, high prevalence of chronic diseases, and growing popularity of minimally invasive procedures, and the presence of prominent players in countries in the region.

Competitive Landscape:

Some of the major key players in the Contrast Media/Contrast Agents Market are GE Healthcare (US), Bracco Imaging SPA (Italy), Bayer AG (Germany), Guerbet (France), Lantheus Medical Imaging Inc. (US), Unijules Life Sciences (India), J.B. Chemicals and Pharmaceuticals Ltd. (India), SANOCHEMIA Pharmazeutika GmbH (Austria), Taejoon Pharm (South Korea), Jodas Expoim (India), Nano Therapeutics Pvt. Ltd. (India), Kiran X-ray (India), iMax Diagnostic Imaging Limited (Ireland), YZJ Group (China), Livealth Biopharma Pvt. Ltd. (India), Trivitron Healthcare Pvt. Ltd. (India), Novalek Pharmaceuticals Pvt. Ltd. (India), Unispire Biopharma Private Limited (India), Acro Lifesciences (I) Pvt. Ltd. (India), Congruent Pharmachem Private Limited (India), Stanex Drugs & Chemical Pvt. Ltd. (India), Beijing Beilu Pharmaceutical Co., Ltd. (China), Rege Imaging & Cine Films Private Limited (India), K DIAM EXIM (India), Onko Ýlaç San. ve Tic. A.Þ. (Turkey), and Subhra Pharma Pvt. Ltd. (India)

Contrast Media/Contrast Agents Market is Segmented as Follows:

Parameter Details
Segments Covered
  • Type (Iodinated Contrast Media, Gadolinium- Based Contrast Media, Microbubble Contrast Media, Barium- Based Contrast Media)
  • Modality (X- Ray/ CT, MRI, Ultrasound)
  • Administration (Intravascular Route, Oral Route, Rectal Route, Others)
  • Indication (Cardiovascular Disorders, Cancer, Gastrointestinal Disorders, Musculoskeletal Disorders, Neurological Disorders, Nephrological Disorders)
  • Application (Radiology, Interventional Radiology, Interventional Cardiology)
  • End User (Hospital, Clinics, & Ambulatory Surgery Centers, Diagnostic Imaging Centers)
  • Regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)
Regions & Countries Covered
  • North America - (U.S., Canada, Mexico)
  • Europe - (U.K., France, Germany, Italy, Spain, Rest Of Europe)
  • Asia Pacific - (China, Japan, India, South Korea, South East Asia, Rest Of Asia Pacific)
  • Latin America - (Brazil, Argentina, Rest Of Latin America)
  • Middle East & Africa - (GCC Countries, South Africa, Rest Of Middle East & Africa)
Companies Covered
  • GE Healthcare (US)
  • Bracco Imaging SPA (Italy)
  • Bayer AG (Germany)
  • Guerbet (France)
  • Lantheus Medical Imaging Inc. (US)
  • Unijules Life Sciences (India)
  • J.B. Chemicals and Pharmaceuticals Ltd. (India)
  • SANOCHEMIA Pharmazeutika GmbH (Austria)
  • Taejoon Pharm (South Korea)
  • Jodas Expoim (India)
  • Nano Therapeutics Pvt. Ltd. (India)
  • Kiran X-ray (India)
  • iMax Diagnostic Imaging Limited (Ireland)
  • YZJ Group (China)
  • Livealth Biopharma Pvt. Ltd. (India)
  • Trivitron Healthcare Pvt. Ltd. (India)
  • Novalek Pharmaceuticals Pvt. Ltd. (India)
  • Unispire Biopharma Private Limited (India)
  • Acro Lifesciences (I) Pvt. Ltd. (India)
  • Congruent Pharmachem Private Limited (India)
  • Stanex Drugs & Chemical Pvt. Ltd. (India)
  • Beijing Beilu Pharmaceutical Co. Ltd. (China)
  • Rege Imaging & Cine Films Private Limited (India)
  • K DIAM EXIM (India)
  • Onko Ýlaç San. ve Tic. A.Þ. (Turkey)
  • and Subhra Pharma Pvt. Ltd. (India)
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market attractiveness analysis by segments and North America, company market share analysis, and COVID-19 impact analysis

Contrast Media/Contrast Agents Market is Tabulated as Follows:

FAQ
Frequently Asked Question
  • The global Contrast Media/Contrast Agents valued at USD 4,729.20 Million in 2020 and is expected to reach USD 5,813.30 Million in 2028 growing at a CAGR of 3.5%.

  • The prominent players in the market are GE Healthcare (US), Bracco Imaging SPA (Italy), Bayer AG (Germany), Guerbet (France), Lantheus Medical Imaging Inc. (US), Unijules Life Sciences (India), J.B. Chemicals and Pharmaceuticals Ltd. (India), SANOCHEMIA Pharmazeutika GmbH (Austria), Taejoon Pharm (South Korea), Jodas Expoim (India), Nano Therapeutics Pvt. Ltd. (India), Kiran X-ray (India), iMax Diagnostic Imaging Limited (Ireland), YZJ Group (China), Livealth Biopharma Pvt. Ltd. (India), Trivitron Healthcare Pvt. Ltd. (India), Novalek Pharmaceuticals Pvt. Ltd. (India), Unispire Biopharma Private Limited (India), Acro Lifesciences (I) Pvt. Ltd. (India), Congruent Pharmachem Private Limited (India), Stanex Drugs & Chemical Pvt. Ltd. (India), Beijing Beilu Pharmaceutical Co., Ltd. (China), Rege Imaging & Cine Films Private Limited (India), K DIAM EXIM (India), Onko Ýlaç San. ve Tic. A.Þ. (Turkey), and Subhra Pharma Pvt. Ltd. (India).

  • The market is project to grow at a CAGR of 3.5% between 2021 and 2028.

  • The driving factors of the Contrast Media/Contrast Agents include

    • Rising prevalence of chronic diseases

  • North America was the leading regional segment of the Contrast Media/Contrast Agents in 2020.